Better Therapeutics (BTTX)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 6, 2024 03:30 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Better Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 16 | 41 | 0 | -99,999 |
Receivables | NA | 0 | 0 | 0 | NA |
Notes Receivable | NA | 0 | 0 | 0 | NA |
Inventories | NA | 0 | 0 | 0 | NA |
Other Current Assets | NA | 3 | 5 | 0 | NA |
Total Current Assets | NA | 18 | 45 | 0 | NA |
Net Property & Equipment | NA | 4 | 5 | 0 | NA |
Investments & Advances | NA | 0 | 0 | 0 | NA |
Other Non-Current Assets | NA | 0 | 0 | 0 | NA |
Deferred Charges | NA | 0 | 0 | 0 | NA |
Intangibles | NA | 0 | 0 | 0 | NA |
Deposits & Other Assets | NA | 0 | 1 | 0 | NA |
Total Assets | NA | 23 | 51 | 0 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | NA |
Accounts Payable | NA | 3 | 2 | 0 | NA |
Current Portion Long-Term Debt | NA | 5 | 0 | 0 | NA |
Current Portion Capital Leases | NA | 0 | 0 | 0 | NA |
Accrued Expenses | NA | 6 | 3 | 0 | NA |
Income Taxes Payable | NA | 0 | 0 | 0 | NA |
Other Current Liabilities | NA | 0 | 0 | 0 | NA |
Total Current Liabilities | NA | 13 | 5 | 0 | NA |
Mortgages | NA | 0 | 0 | 0 | NA |
Deferred Taxes/Income | NA | 0 | 0 | 0 | NA |
Convertible Debt | NA | 0 | 0 | 0 | NA |
Long-Term Debt | NA | 10 | 10 | 0 | NA |
Non-Current Capital Leases | NA | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | NA |
Total Liabilities | NA | 24 | 14 | 0 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | NA |
Common Stock (Par) | NA | 0 | 0 | 0 | NA |
Capital Surplus | NA | 111 | 108 | 0 | NA |
Retained Earnings | NA | -112 | -72 | 0 | NA |
Other Equity | NA | 0 | 0 | 0 | NA |
Treasury Stock | NA | 0 | 0 | 0 | NA |
Total Shareholder's Equity | NA | -1 | 37 | 0 | NA |
Total Liabilities & Shareholder's Equity | NA | 23 | 51 | 0 | NA |
Total Common Equity | 0 | -1 | 37 | 0 | 0 |
Shares Outstanding | 49.80 | 23.80 | 23.60 | 1.40 | NA |
Book Value Per Share | 0.00 | -0.04 | 1.56 | 0.01 | 0.00 |
Fiscal Year End for Better Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 7 | 6 |
Receivables | NA | NA | NA | 0 | 0 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 0 | 0 |
Other Current Assets | NA | NA | NA | 1 | 1 |
Total Current Assets | NA | NA | NA | 7 | 7 |
Net Property & Equipment | NA | NA | NA | 3 | 4 |
Investments & Advances | NA | NA | NA | 0 | 0 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 0 | 0 |
Intangibles | NA | NA | NA | 0 | 0 |
Deposits & Other Assets | NA | NA | NA | 0 | 0 |
Total Assets | NA | NA | NA | 11 | 12 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | 0 |
Accounts Payable | NA | NA | NA | 2 | 3 |
Current Portion Long-Term Debt | NA | NA | NA | 7 | 6 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 4 | 5 |
Income Taxes Payable | NA | NA | NA | 0 | 0 |
Other Current Liabilities | NA | NA | NA | 0 | 0 |
Total Current Liabilities | NA | NA | NA | 13 | 14 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 0 | 0 |
Convertible Debt | NA | NA | NA | 0 | 0 |
Long-Term Debt | NA | NA | NA | 8 | 9 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 21 | 22 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 0 | 0 |
Capital Surplus | NA | NA | NA | 124 | 118 |
Retained Earnings | NA | NA | NA | -134 | -128 |
Other Equity | NA | NA | NA | 0 | 0 |
Treasury Stock | NA | NA | NA | 0 | 0 |
Total Shareholder's Equity | NA | NA | NA | -10 | -11 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 11 | 12 |
Total Common Equity | 0 | 0 | 0 | -10 | -11 |
Shares Outstanding | 49.80 | 49.80 | 49.80 | 40.50 | 31.70 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | -0.25 | -0.34 |